View Post

IU Precision Health Initiative has dramatic results for triple negative breast cancer patient

In Clinical Trials by Barbara Jacoby

By: Christine Drury From: iu.edu Five years ago, Jackie Stephens rolled over in bed and felt a horrible pain in her right breast. A subsequent mammogram revealed a large lump in her right breast and two smaller ones. Her diagnosis: triple negative breast cancer. Stephens’ oncologist prescribed a treatment regimen of chemotherapy, a lumpectomy and radiation. When her treatment was …

View Post

Biovica Publishes a Summary of Study-results in Breast Cancer With DiviTum®

In Clinical Trials by Barbara Jacoby

This information was brought to you by Cision http://news.cision.com From: biospace.com Biovica has a comprehensive study program with DiviTum® to demonstrate the clinical value for cancer patients. Biovica has published a summary brochure in order to share knowledge about results achieved so far with DiviTum® to researchers, oncologists and other stakeholders. The summary describes all clinical studies presented where DiviTum® …

View Post

Investigators Slow Growth by Starving Triple-Negative Breast Cancer Cells

In Clinical Trials by Barbara Jacoby

By: Jennifer Nesse From: specialtypharmacytimes.com Investigators from the Brazilian Biosciences National Laboratory have developed a strategy for slowing the growth of triple-negative breast cancer (TNBC) that involves cutting cancerous cells off from vital food sources. The study, published in the Journal of Biological Chemistry, focused on TNBC tumors, which often lack estrogen progesterone receptors and human epidermal growth factor receptor …

View Post

Metastatic Breast Cancer Genomes Point to Distinct Features, Tumor Evolution

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com A team from France, Switzerland, and the US has characterized genomic alterations that are specific to advanced, metastatic forms of breast cancer using exome sequence and clinical outcome data. As they reported online today in Nature, the researchers did whole-exome sequencing on samples from more than 600 individuals with metastatic breast cancer, identifying alterations that …

View Post

Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: yahoo.com Positive opinion based on results from largest Phase 3 trial performed to date of a PARP inhibitor in gBRCA-mutated advanced breast cancer Pfizer Inc. (PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase …

View Post

Straight to the lungs: Inhaled chemo lessens collateral damage

In Clinical Trials by Barbara Jacoby

By: Katrina Burton From: mdanderson.org MD Anderson researchers are examining the use of inhaled chemotherapy to treat cancer that has spread to the lungs from other sites in the body. They hope to find that the inhaler delivers the chemotherapy drug directly to the lungs where it treats lung tumors while sparing healthy organs. A new way of treating cancer …

View Post

IACS and other platforms develop new cancer treatments for clinical trials

In Clinical Trials by Barbara Jacoby

By: Clayton R. Boldt, Ph.D. From: mdanderson.org Therapeutics Discovery scientists bring clinical cancer research to the lab and use unique model for drug development to benefit cancer patients. “From the bench to the bedside” is a phrase often used to describe a drug discovery’s journey from the laboratory to the clinic, where patients benefit. MD Anderson’s Therapeutics Discovery division, however, …

View Post

Barriers to Cancer Clinical Trial Enrollment

In Clinical Trials by Barbara Jacoby

By: Andrea S. Blevins Primeau, PhD, MBA From: cancertherapyadvisor.com Clinical trials are critical to developing new therapies and improving existing regimens for better efficacy and safety.1 Clinical trials can only be conducted if they enroll sufficient numbers of patients, and the more rapid the accrual, the sooner results can be collected and analyzed, and, ultimately, translated to the clinical setting. …

View Post

CRUK tests drug combo for advanced pancreatic cancer

In Clinical Trials by Barbara Jacoby

From: pharmaphorum.com Cancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in advanced pancreatic cancer as part of its Combinations Alliance. The novel combination of drugs targets the process of nerve invasion, observed in over 80% of pancreatic ductal adenocarcinoma (PDAC) and is associated with tumour spread and severe pain. The PAGoDA …

View Post

Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab

In Clinical Trials by Barbara Jacoby

Source: Checkpoint Therapeutics, Inc From: apnews.com >40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support potential BLA submissions Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with …